米拉贝格朗对Langendorff透的子心室中心房动的抗心律效应
Xiao Liu1, Yen-Ling Sung1,2, Liyang Zhang1
1Department of Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
The Journal of physiology
|March 15, 2025
概括
米拉贝格伦是一种β-3上腺素受体激动剂,通过减少心室动,显示出抗心律失常的效果. 这些有益影响在雌性比雄性子更为明显,这表明潜在的性别特异性治疗应用.
科学领域:
- 心血管药理学心血管药理学
- 心脏电生理学 心脏电生理学
- 上腺受体信号传递
背景情况:
- 过度的catecholamine活性可以引发心律失常,如心室动 (VF).
- β-3上腺素受体 (AR) 抵消β-1和β-2上腺素受体的影响,可能减轻甲醇胺诱导的心律失常.
- 米拉贝格朗是一种FDA批准的β-3AR激动剂.
研究的目的:
- 为了研究β-3AR激动剂mirabegron能否逆转子心脏中异质醇 (ISO) 诱导的心室动 (VF).
- 为了确定Mirabegron抗心律失常功效的潜在基于性别的差异.
- 评估mirabegron对离子电流的直接影响,特别是对apamin敏感的小导电性Ca2+激活K+电流 (IKAS).
主要方法:
- 在Langendorff浸透的雄性和雌性子心脏中进行光学映射研究.
- 异二醇 (ISO),mirabegron和apamin的连续使用.
- 在人类胚胎脏293个细胞中进行了贴片研究,以评估IKAS.
- 定量PCR用于评估性别之间的β-3 AR表达差异.
主要成果:
- 异二醇在女性中增加了每次VF情节 (PSs/VF) 的相异常,并在两性中增加了主导频率 (DF).
- 米拉贝格伦在男性和女性中显著降低了PSs/VF,而女性则显著降低了DF.
- 在更高度 (750-1000 nm) 的情况下,Mirabegron的抗失律作用 (较低的PSs/VF) 在女性中比男性更为明显.
- 米拉贝格朗不抑制或激活IKAS,并且在β-3 AR表达中没有观察到性别差异.
结论:
- 米拉贝格朗表现出显著的抗失律性质,有效地减少心室的标志物.
- 米拉贝格朗的抗心律失常疗效在雌性比雄性子心室中更为突出.
- 这些发现支持了mirabegron作为心律失常治疗剂的潜力,并考虑了潜在的性别特异性考虑.
相关概念视频
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
879
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
879
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
746
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
746
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
695
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
695
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.2K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.2K
01:28Disturbances in Heart Rhythm
812
Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
Arrhythmias are categorized by their speed, rhythm, and origin. A slow...
812
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
356
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
356